{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:59:21Z","timestamp":1784552361319,"version":"3.55.0"},"reference-count":96,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBL-E) are increasing worldwide. Carbapenems are usually regarded as the antibiotics of choice for the treatment of serious ESBL infections. However, because of the alarming emergence or carbapenem resistance, interest in effective alternatives has emerged. The present review summarizes the findings published on the antibiotics currently available for treatment of patients with an ESBL-E bloodstream infection (BSI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Meropenem and imipenem are the drugs recommended for treatment of ESBL BSIs in critically ill patients, and in infections with high bacterial loads or elevated \u03b2-lactam minimum inhibitory concentrations. Ertapenem should be reserved for patients with less severe presentations, and should be used at high doses. In milder presentations or BSIs from low-risk sources, other carbapenem-sparing alternatives could be considered: cephamycins, fluoroquinolones, and particularly a \u03b2-lactam\/\u03b2-lactam inhibitor combination (particularly piperacillin\/tazobactam). Optimized dosing of piperacillin\/tazobactam is recommended (high doses and extended infusion). There are few data on the use of the promising newly available drugs (e.g. ceftolozane\/tazobactam, ceftazidime\/avibactam, cefiderocol, and plazomicin), and it seems reasonable to reserve them as last-resort drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Carbapenems should be used in patients with serious infections; alternatives could be used individually, particularly for definitive treatment of patients with milder presentations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000646","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T16:13:47Z","timestamp":1564676027000},"page":"438-448","source":"Crossref","is-referenced-by-count":12,"title":["Optimizing therapy of bloodstream infection due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae"],"prefix":"10.1097","volume":"25","author":[{"given":"Carlota","family":"Gudiol","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona"},{"name":"REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona"},{"name":"REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona"},{"name":"REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20230913","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSACPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmi.2016.01.023","article-title":"Antibacterial Resistance Leadership Group. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumonia infections","volume":"22","author":"Hauck","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum (-lactamases: A systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenem versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1128\/AAC.01450-09","article-title":"Worldwide experience with the use of doripenem against extended-spectrum- (-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies","volume":"54","author":"Kaniga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular \u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resist","volume":"52","author":"Mendes","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.06301-11","article-title":"Carbapenem therapy for bacteremia due to extended-spectrum-(-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility","volume":"56","author":"Lee","year":"2012","journal-title":"Antimcrob Agents Chemother"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.05913-11","article-title":"Efficacy of ertapenem for treatment of bloodstream infections caused by extended spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"56","author":"Collins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational preregistered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/dkl485","article-title":"Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration","volume":"59","author":"Burkhardt","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1093\/jac\/dku149","article-title":"Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum (-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model","volume":"69","author":"Zhanel","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1099\/jmm.0.012468-0","article-title":"Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum \u03b2-lactamase","volume":"59","author":"Skurnik","year":"2010","journal-title":"J Med Microbiol"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/cc11862","article-title":"A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia","volume":"16","author":"Kollef","year":"2012","journal-title":"Crit Care"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.clinthera.2016.04.035","article-title":"Pathogen prevalence and antimicrobial susceptibility among Enterobacteriaceae causing hospital-associated intra-abdominal infections in adults in the United States (2012\u20132013)","volume":"38","author":"Zalacain","year":"2016","journal-title":"Clin Ther"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jac\/dkv362","article-title":"Impact of the MIC of piperacillin\/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC Project","volume":"71","author":"Delgado-Valverde","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1469-0691.2009.02893.x","article-title":"Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin-clavulanate and piperacillin-tazobactam with extended-spectrum \u03b2-lactamase-producing and extended-spectrum \u03b2-lactamase-nonproducing Escherichia coli isolates","volume":"16","author":"L\u00f3pez-Cerero","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum \u03b2-lactamase producing Enterobacteriaceae: Systematic review and meta-analysis","volume":"52","author":"Sfei","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"ofx09","DOI":"10.1093\/ofid\/ofx099","article-title":"Comparison between carbapenems and \u03b2-lactam\/\u03b2-lactamase inhibitors in the treatment for bloodstream caused by ESBL-producing Enterobacteriaceae: A systematic review and meta-analysis","volume":"4","author":"Muhammed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R25-20230913","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum (-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagnostic Microbiol and Infect Dis"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"2015. Carbapenems versus Piperacillin-Tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Cotrol Hosp Epidemiol"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.2018.19345","article-title":"Antibiotics for ceftriaxone resistant gram-negative bacterial bloodstream infections","volume":"321","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"JAMA"},{"key":"R29-20230913","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00164-17","article-title":"Efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-\u03b2-lactamase-producing enterobacteriaceae in hematological patients with neutropenia","volume":"61","author":"Gudiol","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20230913","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01813-18","article-title":"Carbapenem versus cefepime or piperacillin-tazobactam for the empiric treatment of extended spectrum \u03b2-lactamase producing Escherichia coli bacteremia in patients with hematologic malignancy","volume":"63","author":"Benanti","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20230913","article-title":"Use of \u03b2-lactam\/\u03b2-lactamase inhibitors for extended-spectrum-\u03b2-lactamase infections: defining the right patient population","volume":"61","author":"Tamma","year":"2017","journal-title":"Antimicrob Agents Chemther"},{"key":"R32-20230913","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal (-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R33-20230913","doi-asserted-by":"crossref","first-page":"e0116769","DOI":"10.1371\/journal.pone.0116769","article-title":"Clinical outcomes with alternative dosing strategies for piperacillin-tazobactam: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/jac\/dky323","article-title":"Comparison of empirical therapy with cefoperazone\/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae","volume":"73","author":"Su","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang","year":"2012","journal-title":"J Infect"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post-hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extendedspectrum \u03b2-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R39-20230913","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"R41-20230913","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R42-20230913","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20230913","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance:results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R44-20230913","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infection, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenleher","year":"2015","journal-title":"Lancet"},{"key":"R45-20230913","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R46-20230913","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R47-20230913","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime\/avibactam versus meropenem in the treatment of complicated intra-abdominal infections: results of a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R48-20230913","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomize trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R49-20230913","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intraabdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis 2016;"},{"key":"R50-20230913","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R51-20230913","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","article-title":"In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmi-mediated AmpC \u03b2-lactamase-produginc Enterobacteriaceae","volume":"84","author":"Matsumura","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R52-20230913","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/JCM.37.12.4020-4027.1999","article-title":"Bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes","volume":"37","author":"Siu","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R53-20230913","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2334-12-206","article-title":"Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum \u03b2-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis","volume":"12","author":"Yang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R54-20230913","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","article-title":"Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective","volume":"46","author":"Lee","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R55-20230913","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R56-20230913","doi-asserted-by":"crossref","first-page":"1105.e1","DOI":"10.1016\/j.cmi.2015.07.025","article-title":"Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R57-20230913","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R58-20230913","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/IDR.S146923","article-title":"Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaximeresistant enterobacteriaceae bacteremia","volume":"11","author":"Lee","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R59-20230913","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijantimicag.2018.01.008","article-title":"Cefoxitin-based antibiotic therapy for extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study","volume":"51","author":"Demonchy","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R60-20230913","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R61-20230913","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00447-06","article-title":"Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions","volume":"44","author":"Oteo","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R62-20230913","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients","volume":"12","author":"Goethaert","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"R63-20230913","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing enterobacteriaceae","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R64-20230913","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum \u03b2-lactamase-producing enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R65-20230913","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase-producing enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R66-20230913","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In vitro killing of parenteral \u03b2-lactams against standard and high inocula of extended-spectrum \u03b2-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R67-20230913","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.48.6.1941-1947.2004","article-title":"Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-\u03b2-lactamase-producing Escherichia coli at various inocula","volume":"48","author":"Maglio","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R68-20230913","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/jac\/dkv153","article-title":"Mutagenesis of the CTX-M-type ESBL\u2014is MIC-guided treatment according to the new EUCAST recommendations a safe approach?","volume":"70","author":"Costa Ramos","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R69-20230913","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against nonfermenting Gram-negative bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R70-20230913","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, noninferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R71-20230913","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R72-20230913","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijantimicag.2017.06.014","article-title":"Activity of temocillin against CTX-M-producing Escherichia coli and Klebsiella pneumoniae from Germany","volume":"51","author":"Kresken","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R73-20230913","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/jac\/dky569","article-title":"Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates","volume":"74","author":"Alexandre","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R74-20230913","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkp208","article-title":"Clinical efficacy of temocillin","volume":"64","author":"Gupta","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R75-20230913","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R76-20230913","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R77-20230913","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R78-20230913","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R79-20230913","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2\/3 randomized trial","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R80-20230913","doi-asserted-by":"crossref","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"5","author":"Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open"},{"key":"R81-20230913","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2016.04.017","article-title":"Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance","volume":"48","author":"Pournaras","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R82-20230913","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.01154-12","article-title":"The therapeutic effect of tigecycline, unlike that of ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum \u03b2-lactamases in experimental pneumonia in rats","volume":"57","author":"Goessens","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"(Suppl 1:i)","key":"R83-20230913","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkn249","article-title":"A phase 3, open-label, noncomparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae","volume":"62","author":"Vasilev","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R84-20230913","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-014-0691-4","article-title":"Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria","volume":"43","author":"Heizmann","year":"2015","journal-title":"Infection"},{"key":"R85-20230913","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R86-20230913","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R87-20230913","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diagmicrobio.2005.08.018","article-title":"In vitro activity of \u03b2-lactam and non-\u03b2-lactam antibiotics in extended-spectrum \u03b2-lactamase-producing clinical isolates of Escherichia coli","volume":"54","author":"Puerto","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R88-20230913","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2016.09.001","article-title":"Plasmid-mediated quinolone resistance: two decades on","volume":"29","author":"Rodr\u00edguez-Mart\u00ednez","year":"2016","journal-title":"Drug Resist Updat"},{"key":"R90-20230913","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.05.004","article-title":"Nonintravenous carbapenem-sparing antibiotics for the definitive treatment of bacteremia due to Enterobacteriaceae-producing ESBL or Amp-C \u03b2-lactamase. A propensity score study","author":"Meije","year":"2019","journal-title":"Inter J Antimicrob Agents"},{"key":"R91-20230913","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: results from the INCREMENT cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R92-20230913","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s15010-016-0968-x","article-title":"Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series","volume":"45","author":"Murri","year":"2017","journal-title":"Infection"},{"key":"R93-20230913","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijantimicag.2018.03.014","article-title":"Which noncarbapenem antibiotics are active against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae?","volume":"52","author":"Bouxom","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R94-20230913","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R95-20230913","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkp411","article-title":"Bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome","volume":"65","author":"Gudiol","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R96-20230913","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/mdr.2014.0092","article-title":"Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children","volume":"21","author":"Han","year":"2015","journal-title":"Microb Drug Resist"},{"key":"R97-20230913","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: A novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"R98-20230913","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:40:29Z","timestamp":1694634029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000646","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}